Clinical Trial Detail

NCT ID NCT02824575
Title Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Montefiore Medical Center
Indications

Her2-receptor negative breast cancer

Therapies

Paclitaxel + Rebastinib

Eribulin + Rebastinib

Age Groups: adult senior

Additional content available in CKB BOOST